OMER Profile
Omeros Corporation, based in Seattle, Washington, is a biopharmaceutical company at the forefront of discovering, developing, and commercializing innovative small-molecule and protein therapeutics. Established in 1994, Omeros focuses on addressing complex medical conditions such as inflammation, complement-mediated diseases, cancer associated with immune system dysfunction, and addictive and compulsive disorders.
The company's diverse clinical pipeline includes Narsoplimab (OMS721/MASP-2), a pivotal therapy that has completed studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is currently in Phase III trials for conditions like immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS). Additionally, Narsoplimab is being investigated in Phase II trials for its potential to treat COVID-19.
Omeros also advances therapeutic candidates such as PPAR? (OMS405) for opioid and nicotine addiction, PDE7 (OMS527) for addiction and compulsive disorders, and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and related disorders, all in various stages of clinical trials.
Beyond its clinical programs, Omeros pursues robust preclinical research initiatives, including MASP-2 small-molecule inhibitors for treating aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. The company also explores potential therapies such as longer-acting antibodies targeting MASP-2, MASP-3 small-molecule inhibitors, GPR174 inhibitors, and innovative CAR T-cell therapies for diverse cancers and other immunological and metabolic disorders. With a steadfast commitment to advancing medical science, Omeros Corporation continues to drive innovation in biopharmaceuticals to benefit patients worldwide.
|
